An update on Long COVID - symptoms and underlying pathology
Event details
The Institute for Pandemics (IfP) presents a lecture by Dr. Manali Mukherjee of McMaster University titled, “An update on Long COVID – symptoms and underlying pathology.” The learning objectives are:
- Disseminate findings from the CITF-funded AIPACs study (Autoimmunity in Post Acute COVID-19 Sequalae)
- Understand the immunological underpinning for the development of autoimmune diseases in Long COVID
- Understand and review the different phenotypes of Long COVID sufferers
This lecture is offered in a hybrid format. Limited space is available for folks to attend in person at the University of Toronto St. George campus or view online via Zoom.
NOTE: This event will not be recorded.
About the presenter
Dr. Manali Mukherjee is an Assistant Professor in the Division of Respirology, Department of Medicine, McMaster University and a translational scientist affiliated with the Research Institute of St. Joe's, Hamilton. She has demonstrated expertise in investigating inflammatory mechanisms of chronic respiratory diseases, in particular autoimmunity, response to treatment and development/ validation of clinical biomarkers. Her research has identified the presence of localized autoimmune responses in the airways of patients with complex airways disease and determined their pathogenic role in driving disease severity. Of recent, she has identified autoimmune responses in acute-severe COVID and linked autoimmunity with post-acute COVID-19 sequelae (or Long COVID). In the field of respiratory medicine, she published ~65 manuscripts, and in the past 5 years these have accumulated >2000 citations (Google Scholar h-index 23, i10-index 37).
Dr. Mukherjee’s research program focuses on “Lung autoimmunity and biomarkers”. She is the past recipient of the Emerging Researcher Award in Allergic Asthma awarded conjointly by the Canadian Institutes of Health Research (CIHR) and the Canadian Asthma, Allergy and Immunology Foundation (CAAIF). Her lab is funded by federal and non-federal sources including CIHR-ICRH and industry. Dr Mukherjee was recently named the AstraZeneca Chair in Respiratory Diseases (2023-2028).